A phase II, double-blind, placebo-controlled, randomized clinical trial assessing toxicity and efficacy of MF101 for hot flashes and menopausal symptoms
Latest Information Update: 03 Nov 2021
At a glance
- Drugs MF 101 (Primary)
- Indications Hot flashes; Menopausal syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHIMES
- 18 Jan 2012 Study acronym added
- 18 Jan 2012 Results of a re-analysis published in Climacteric.
- 12 Jun 2011 Results presented at the 13th World Congress on Menopause.